S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
New "Mined in America" Lithium Opportunities? (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
New "Mined in America" Lithium Opportunities? (Ad)
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
Workday: Another AI Winner Melting-Up 
The Graphite Shortage Story You're Not Being Told (Ad)
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
Taiwan Semiconductor Well Positioned for the AI Rush
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
New "Mined in America" Lithium Opportunities? (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
New "Mined in America" Lithium Opportunities? (Ad)
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
Workday: Another AI Winner Melting-Up 
The Graphite Shortage Story You're Not Being Told (Ad)
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
Taiwan Semiconductor Well Positioned for the AI Rush
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
New "Mined in America" Lithium Opportunities? (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
New "Mined in America" Lithium Opportunities? (Ad)
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
Workday: Another AI Winner Melting-Up 
The Graphite Shortage Story You're Not Being Told (Ad)
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
Taiwan Semiconductor Well Positioned for the AI Rush
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
New "Mined in America" Lithium Opportunities? (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
New "Mined in America" Lithium Opportunities? (Ad)
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
Workday: Another AI Winner Melting-Up 
The Graphite Shortage Story You're Not Being Told (Ad)
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
Taiwan Semiconductor Well Positioned for the AI Rush
NASDAQ:BSTC

BioSpecifics Technologies (BSTC) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$88.53
▼
$88.53
50-Day Range
$88.22
▼
$88.53
52-Week Range
$42.00
▼
$89.15
Volume
N/A
Average Volume
61,105 shs
Market Capitalization
$650.25 million
P/E Ratio
37.51
Dividend Yield
N/A
Price Target
N/A
ProfileFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

BSTC stock logo

About BioSpecifics Technologies (NASDAQ:BSTC) Stock

BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.

Receive BSTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioSpecifics Technologies and its competitors with MarketBeat's FREE daily newsletter.

BSTC Stock News Headlines

March 21, 2023 | bizjournals.com
Silicon Valley Technology News
May 14, 2021 | nasdaq.com
BioSpecifics Technologies Corp. Common Stock (BSTC)
May 30, 2023 | Edge On The Street (Ad)
Is Graphite the New Lithium?
Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.
December 3, 2020 | finance.yahoo.com
Estimating The Fair Value Of BioSpecifics Technologies Corp. (NASDAQ:BSTC)
November 19, 2020 | stockhouse.com
BioSpecifics Merger Investigation: Halper Sadeh LLP Encourages BioSpecifics Technologies Corp. Shareholders to Contact the Firm - BSTC
November 18, 2020 | finance.yahoo.com
Endo Announces Expiration Of Hart-Scott-Rodino Waiting Period For BioSpecifics Tender Offer
November 18, 2020 | benzinga.com
BioSpecifics Merger Investigation: Halper Sadeh LLP Encourages BioSpecifics Technologies Corp. Shareholders to Contact the Firm – BSTC
November 17, 2020 | finance.yahoo.com
WeissLaw LLP Reminds BSTC, DNKN, NAV, and PNM, Shareholders About Its Ongoing Investigations
May 30, 2023 | Edge On The Street (Ad)
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
November 13, 2020 | finance.yahoo.com
Moore Kuehn Encourages BSTC Investors to Contact Law Firm
November 11, 2020 | apnews.com
Rigrodsky & Long, P.A. Reminds Investors Of Investigation of BioSpecifics Technologies ...
November 10, 2020 | benzinga.com
Rigrodsky & Long, P.A. Reminds Investors Of Investigation of BioSpecifics Technologies Corp. Buyout
November 9, 2020 | finance.yahoo.com
BioSpecifics Technologies (BSTC) Surpasses Q3 Earnings and Revenue Estimates
November 9, 2020 | finance.yahoo.com
BioSpecifics Reports Third Quarter 2020 Financial and Operating Results
November 7, 2020 | finance.yahoo.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers; Investors are Encouraged to Contact the Firm – BSTC, CBLI, PE, GLIBA
November 6, 2020 | nasdaq.com
Earnings Preview: BioSpecifics Technologies (BSTC) Q3 Earnings Expected to Decline
November 5, 2020 | finance.yahoo.com
Moore Kuehn Encourages TNAV, PRCP, ALSK, and BSTC Investors to Contact Law Firm
November 4, 2020 | bizjournals.com
Inside the deal: Why Endo agreed to pay $658M for a Wilmington biotech company with 5 employees
November 4, 2020 | businesswire.com
BIOSPECIFICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioSpecifics ...
November 4, 2020 | finance.yahoo.com
SHAREHOLDER ALERT: WeissLaw LLP Investigates BioSpecifics Technologies Corp.
November 2, 2020 | finance.yahoo.com
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of BioSpecifics Technologies Corp. (NasdaqGS - BSTC)
October 29, 2020 | finance.yahoo.com
ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Investigations - GLIBA, CXO, RESI, BSTC
October 27, 2020 | finance.yahoo.com
MERGER ALERT - BSTC, BBIO, and PNM: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
October 26, 2020 | finance.yahoo.com
BIOSPECIFICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioSpecifics Technologies Corp. - BSTC
October 21, 2020 | finance.yahoo.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP is Investigating the Following Companies; Investors are Encouraged to Contact the Firm - RESI, BSTC, CIT
October 21, 2020 | news.yahoo.com
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of BioSpecifics Technologies Corp. - BSTC
October 19, 2020 | morningstar.com
Thinking about buying stock in BioSpecifics Technologies, Front Yard Residential, Edesa Biotech, Cinemark Holdings, or Lithium Americas?
See More Headlines

Receive BSTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioSpecifics Technologies and its competitors with MarketBeat's FREE daily newsletter.

BSTC Company Calendar

Last Earnings
11/14/2020
Today
5/29/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BSTC
CUSIP
09093110
CIK
875622
Web
www.biospecifics.com
Phone
302-842-8450
Fax
N/A
Employees
7
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
$3.33
Trailing P/E Ratio
37.51
Forward P/E Ratio
61.91
P/E Growth
N/A
Net Income
$24.47 million
Net Margins
47.43%
Pretax Margin
N/A
Return on Equity
14.81%
Return on Assets
14.46%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
66.24
Quick Ratio
66.24

Sales & Book Value

Annual Sales
$38.19 million
Price / Sales
17.03
Cash Flow
$3.38 per share
Price / Cash Flow
26.18
Book Value
$18.42 per share
Price / Book
4.81

Miscellaneous

Outstanding Shares
7,345,000
Free Float
N/A
Market Cap
$650.25 million
Optionable
Not Optionable
Beta
0.24

Key Executives

  • Dr. Ronald Law J.D. (Age 67)
    Ph.D., Sr. VP of Bus. Devel.
    Comp: $487.38k
  • Mr. Joseph Truitt (Age 55)
    CEO & Director
  • Mr. Patrick C. Hutchison (Age 61)
    Chief Financial Officer
  • Mr. Alex Monteith
    Sr. VP & Chief Bus. Officer
  • Carl A. Valenstein
    Corp. Sec.

Key Competitors

View All Competitors













BSTC Stock - Frequently Asked Questions

How were BioSpecifics Technologies' earnings last quarter?

BioSpecifics Technologies Corp. (NASDAQ:BSTC) announced its quarterly earnings results on Saturday, November, 14th. The biopharmaceutical company reported $0.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.70. The biopharmaceutical company earned $11.26 million during the quarter, compared to the consensus estimate of $5.46 million. BioSpecifics Technologies had a trailing twelve-month return on equity of 14.81% and a net margin of 47.43%.

What other stocks do shareholders of BioSpecifics Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioSpecifics Technologies investors own include AbbVie (ABBV), NVIDIA (NVDA), Pfizer (PFE), Biogen (BIIB), Johnson & Johnson (JNJ), Horizon Therapeutics Public (HZNP), Inovio Pharmaceuticals (INO), Intel (INTC), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

What is BioSpecifics Technologies' stock symbol?

BioSpecifics Technologies trades on the NASDAQ under the ticker symbol "BSTC."

What is BioSpecifics Technologies' stock price today?

One share of BSTC stock can currently be purchased for approximately $88.53.

How much money does BioSpecifics Technologies make?

BioSpecifics Technologies (NASDAQ:BSTC) has a market capitalization of $650.25 million and generates $38.19 million in revenue each year. The biopharmaceutical company earns $24.47 million in net income (profit) each year or $3.33 on an earnings per share basis.

How can I contact BioSpecifics Technologies?

BioSpecifics Technologies' mailing address is 2 Righter Parkway Suite 200, Wilmington DE, 19803. The official website for the company is www.biospecifics.com. The biopharmaceutical company can be reached via phone at 302-842-8450 or via email at biospe-info@biospecifics.com.

This page (NASDAQ:BSTC) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -